Bladder cancer
UPDATED --- First-line therapy of synchronous and metachronous metastatic UCa

Serge (75 years old)

Serge, 75 years old, spends his afternoons listening to old jazz records, meticulously organising his vast collection.

He was diagnosed with MIBC cT2N0M0 and underwent RC without receiving neoadjuvant chemotherapy because he was cisplatin ineligible. The pathological review of the RC specimen indicated pT2b pN2 (3/10) R0, PD-L1 positive. He received adjuvant nivolumab. First follow-up scans were normal, however, 6 months after the start of nivolumab, treatment with nivolumab is still ongoing, but he presents retroperitoneal lymph nodes and lung metastases.

Assessment summary:

  • Medical history: hypertension, chronic kidney disease
  • ECOG PS: 1
  • CT scan reveals retroperitoneal lymph nodes and lung metastases, biopsy compatible with UCa
  • Peripheral neuropathy: grade 1
  • Audiometric hearing loss: grade 2
  • GFR: 45 ml/min
  • FGFR2/3 mutation status in metastatic biopsy specimen: activating FGFR3 mutation

Which of the following options would you choose for this patient?